An ongoing dialogue on HIV/AIDS, infectious diseases,
October 29th, 2011
Will An Antiretroviral Patch Help Adherence? Doubtful …
Preliminary research suggests that a patch could deliver an AIDS drug to patients … The researchers successfully used transdermal patches to administer 96 percent of an AIDS drug to simulated skin over a week. “Still, the important limitation of pills, regardless of how few there are or even how minimal the side effects, is adherence,” Johnston [the investigator] noted. Research has shown that many patients, if not most, don’t take their pills all the time.
Setting aside for a moment the fact that most patients actually do take their medications just fine, thank you — and that this particular transdermal HIV drug delivery system hasn’t even been tested on animals, let alone humans — I have always wondered about the assumption that novel drug delivery systems would improve adherence.
Seems to me that the major problem with non-adherent patients isn’t that they can’t take pills.
It’s that they won’t take them.
And I strongly suspect that most would make the same choice when it comes to putting on a patch every day (or even every week).
Paul E. Sax, MD
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Endless Recertification in Medicine — Some Thoughts About the Tests We Take
- My Vote for the Weirdest Antibiotic on the Planet
- Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Modify Treatment Guidelines?
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- Really Rapid Review — Brisbane IAS 2023
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
- Missed Chances for Screening in Persons Newly Diagnosed with HIV: New York City, 2018–2022
- Arboviral Disease Surveillance in the U.S.
- Observations from ID and Beyond: Long-Acting Cabotegravir-Rilpivirine for People Not Taking Oral Therapy — Time to Change Treatment Guidelines?
- Risk for C. difficile Infection Varies Widely with Choice of Antibiotic
- Mpox in Persons with Previous Infection or Vaccination
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster